SY007 in Patients With Acute Ischemic Stroke

Summary

This Phase 1b multiple center, randomized, double-blind, placebo-controlled study is a dose escalation trial evaluating the safety, tolerability, PK characteristics and efficacy of SY-007 after injection in acute ischemicstroke patients. The immunogenicity of SY-007 will be evaluated and this study will provide the recommended dosage for subsequent clinical trials.

Timeline

Start

2023-07-01

Primary completion

2023-12-25

Completion

2023-12-25

Outcome

Outcome not reported

Stopped: “The sponsor decided to suspend the process”

Drugs

Indications